AKT1 and prostate cancer: The anti-prostate-cancer activity of equol is associated with the activation of FOXO3a (one of the forkhead transcription factors involved in apoptosis) through protein kinase B (AKT)-specific signaling pathways, and inhibits the expression of the MDM2 complex (a negative regulator of the tumor suppressor p53) [110].